pyrroles has been researched along with Myeloproliferative-Myelodisplastic Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayers, GD; Cirici, BX; Cross, NCP; Dezern, AE; Elena, C; Fenaux, P; Geissler, K; Gerds, AT; Germing, U; Itzykson, R; Kiladjian, JJ; Kishtagari, A; Komrokji, RS; Luebbert, M; Mendler, JH; Mesa, RA; Montalban-Bravo, G; Moyo, TK; Nazha, A; Onida, F; Padron, E; Patnaik, MM; Pfeilstöecker, M; Platzbecker, U; Pleyer, L; Santini, V; Sanz, GF; Savona, MR; Seegmiller, AC; Solary, E; Steensma, DP; Tibes, R; Valent, P; van de Loosdrecht, AA; Wiseman, DH; Zhang, J | 1 |
1 trial(s) available for pyrroles and Myeloproliferative-Myelodisplastic Diseases
| Article | Year |
|---|---|
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
Topics: Acetonitriles; Cytidine Deaminase; Decitabine; DNA; Humans; Methyltransferases; Myelodysplastic-Myeloproliferative Diseases; Prospective Studies; Pyrazoles; Pyrimidines; Pyrroles; Quality of Life; Syndrome | 2022 |